OPRX

Company Overview — What Does OptimizeRx Corp Do?

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, the company operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, it offers patient programs with treatment and affordability information, lifestyle and condition trackers, internet device connectivity, forms, and surveys. Additionally, the company provides evidence-based physician engagement solution applied to real-world data to assist healthcare providers in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations. It also offers therapy initiation workflow focused on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was found in 2006 and is headquartered in Rochester, Michigan. OptimizeRx Corp (OPRX) is classified as a micro-cap stock in the Industrials sector, specifically within the Business Services industry. The company is led by CEO William J. Febbo and employs approximately 100 people. With a market capitalization of $124M, OPRX is one of the notable companies in the Industrials sector.

OptimizeRx Corp (OPRX) Stock Rating — Reduce (April 2026)

As of April 2026, OptimizeRx Corp receives a Reduce rating with a composite score of 38.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.OPRX ranks #3,042 out of 4,446 stocks in our coverage universe. Within the Industrials sector, OptimizeRx Corp ranks #521 of 756 stocks, placing it in the lower half of its Industrials peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

OPRX Stock Price and 52-Week Range

OptimizeRx Corp (OPRX) currently trades at $6.56. The 52-week high for OPRX is $22.25, which means the stock is currently trading -70.5% from its annual peak. The 52-week low is $5.54, putting the stock 18.4% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is OPRX Overvalued or Undervalued? — Valuation Analysis

OptimizeRx Corp (OPRX) carries a value factor score of 68/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 23.43x, compared to the Industrials sector average of 27.30x — a discount of 14%. The price-to-book ratio stands at 0.96x, versus the sector average of 2.18x. The price-to-sales ratio is 1.25x, compared to 0.51x for the average Industrials stock. On an enterprise value basis, OPRX trades at 2.33x EV/EBITDA, versus 5.63x for the sector.

Overall, OPRX's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

OptimizeRx Corp Profitability — ROE, Margins, and Quality Score

OptimizeRx Corp (OPRX) earns a quality factor score of 45/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -7.0%, compared to the Industrials sector average of 9.1%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -5.1% versus the sector average of 3.3%.

On a margin basis, OptimizeRx Corp reports gross margins of 63.7%, compared to 35.8% for the sector. The operating margin is -7.8% (sector: 6.2%). Net profit margin stands at -11.2%, versus 3.9% for the average Industrials stock. Revenue growth is running at 38.6% on a trailing basis, compared to 6.5% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

OPRX Debt, Balance Sheet, and Financial Health

OptimizeRx Corp has a debt-to-equity ratio of 20.0%, compared to the Industrials sector average of 70.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.04x, indicating strong short-term liquidity. Total debt on the balance sheet is $26M. Cash and equivalents stand at $20M.

OPRX has a beta of 1.52, meaning it is more volatile than the broader market — a $10,000 investment in OPRX would be expected to move 51.7% more than the S&P 500 on any given day. The stability factor score for OptimizeRx Corp is 22/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

OptimizeRx Corp Revenue and Earnings History — Quarterly Trend

In TTM 2026, OptimizeRx Corp reported revenue of $98M and earnings per share (EPS) of $0.28. Net income for the quarter was $-9M. Gross margin was 63.7%. Operating income came in at $-5M.

In FY 2025, OptimizeRx Corp reported revenue of $109M and earnings per share (EPS) of $0.28. Net income for the quarter was $5M. Gross margin was 67.3%. Revenue grew 18.8% year-over-year compared to FY 2024. Operating income came in at $12M.

In Q3 2025, OptimizeRx Corp reported revenue of $26M and earnings per share (EPS) of $0.04. Net income for the quarter was $779,000. Gross margin was 67.2%. Revenue grew 22.3% year-over-year compared to Q3 2024. Operating income came in at $2M.

In Q2 2025, OptimizeRx Corp reported revenue of $29M and earnings per share (EPS) of $0.08. Net income for the quarter was $2M. Gross margin was 63.8%. Revenue grew 55.2% year-over-year compared to Q2 2024. Operating income came in at $3M.

Over the past 8 quarters, OptimizeRx Corp has demonstrated a growth trajectory, with revenue expanding from $19M to $98M. Investors analyzing OPRX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

OPRX Dividend Yield and Income Analysis

OptimizeRx Corp (OPRX) does not currently pay a dividend. This is common among smaller companies in the Business Services industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Industrials dividend stocks may want to explore other Industrials stocks or use the stock screener to filter by dividend yield.

OPRX Momentum and Technical Analysis Profile

OptimizeRx Corp (OPRX) has a momentum factor score of 22/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 23/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 47/100 reflects moderate short selling activity.

OPRX vs Competitors — Industrials Sector Ranking and Peer Comparison

Within the Industrials sector, OptimizeRx Corp (OPRX) ranks #521 out of 756 stocks based on the Blank Capital composite score. This places OPRX in the lower half of all Industrials stocks in our coverage universe. Key competitors and sector peers include Scorpio Tankers Inc. (STNG) with a score of 63.3/100, TSAKOS ENERGY NAVIGATION LTD (TEN) with a score of 61.2/100, TEEKAY TANKERS LTD. (TNK) with a score of 62.2/100, Great Lakes Dredge & Dock CORP (GLDD) with a score of 56.5/100, and Hafnia Ltd (HAFN) with a score of 59.4/100.

Comparing OPRX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full OPRX vs S&P 500 (SPY) comparison to assess how OptimizeRx Corp stacks up against the broader market across all factor dimensions.

OPRX Next Earnings Date

No upcoming earnings date has been announced for OptimizeRx Corp (OPRX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy OPRX? — Investment Thesis Summary

The quantitative profile for OptimizeRx Corp suggests caution. The value score of 68/100 suggests attractive pricing relative to fundamentals. Momentum is weak at 22/100, a headwind for near-term performance. High volatility (stability score 22/100) increases portfolio risk.

In summary, OptimizeRx Corp (OPRX) earns a Reduce rating with a composite score of 38.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on OPRX stock.

Related Resources for OPRX Investors

Explore more research and tools: OPRX vs S&P 500 comparison, top Industrials stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare OPRX head-to-head with peers: OPRX vs STNG, OPRX vs TEN, OPRX vs TNK.